India has a high prevalence of blood cancer and other blood-related disorders like Thalassemia or Aplastic Anemia. Despite a large number of cases, patients suffering from such conditions are forced to struggle with their treatments and therapies. DKMS BMST Foundation India, a non-profit Organisation, is dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and aplastic anemia. It is a joint venture of two reputed Non-profit Organisations: BMST (Bangalore Medical Services Trust) and DKMS, one of the largest international blood stem cell donor centres in the world. Financial Express.com reached out to Patrick Paul, CEO, DKMS BMST Foundation India and he highlighted the status of blood disorders in India, challenges faced by the patients suffering from these diseases and role of DKMS BMST Foundation India in patient care in the country among others. Excerpts:
What are the various types of blood cancers that are prevalent in India?
Blood Cancer typically means malignancies of the blood, bone marrow or lymph nodes that affect normal blood cell production or function.
Of all types of Blood Cancers, here are the three most common types of blood cancer that affects the Indian population mentioned in order of the rate of incidence.
Lymphoma is the name for a group of blood cancers that develop in the lymphatic system. The two main types are Hodgkin lymphoma (generally starts in blood and bone marrow) and non-Hodgkin lymphoma (generally starts in lymph node and lymphatic tissue.)
Leukemia is a blood cancer that develops when normal blood cells change and grow uncontrollably. There are four main types named according to the cells affected (myeloblasts, lymphocytes) and whether the disease starts with mature or immature cells (chronic, acute).
Multiple myeloma starts in the bone marrow when plasma cells begin to grow uncontrollably. As the cells grow, they compromise the immune system and impair the production and function of white and red blood cells causing bone disease, organ damage and anemia among other conditions.
What are the challenges that a blood cancer patient faces in India? What needs to be done to help them in overcoming those hurdles?
Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder such as Thalassemia or Aplastic Anemia. Despite this huge cancer burden, In India, only 0.04% of the total population is registered as a potential blood stem cell donor. While blood cancer is life-threatening, a set of healthy blood stem cells from a matching donor can be life-saving. The demand and supply gap are increasing as people dont register themselves as potential blood stem cell donors due to lack of awareness.
Only about 30% of the patients in need of a stem cell transplant as lifesaving treatment can find a sibling match. The rest 70% depend on finding a matching unrelated donor which makes it vital for people to register themselves as potential donors and help save a life.
How does DKMS BMST Foundation India help patients with blood cancer? In recent years, what are the crucial milestones that the organization has achieved in the country?
DKMS-BMST helps blood cancer patients by:
Raising awareness and educating the general public about the importance of blood stem cell donation
Recruiting donors by encouraging people of diverse ethnicities to register as a potential blood stem cell donor. Recruitment is done through various registration drives at different colleges, corporates, and associations and through online portal.
Matching and collection of stem cells by facilitating search requests in collaboration with transplant centers, collection, processing and transport of stem cell product
Ensuring donor safety and following up post the procedure to monitor the well-being of the donors
Supporting patients and families with information and organization of registration events
Research to advance blood cancer treatment and improve the success rate of transplants
DKMS-BMST has organized over 1300 donor registration drives with focus on South India in the last one year across various organizations such as corporates, educational institutes, hospitals and defense forces to spread awareness about blood stem cell donation and enroll more potential donors. So far, DKMS-BMST have successfully registered over 70,000 potential blood stem cell donors.
While our donor recruitment team is responsible to register potential donors, our medical team works with transplant centers and collection centers. As soon as we receive a direct request from a transplant center for a patient from India or abroad, a worldwide search is started to determine whether there is a donor available. If there is a donor from DKMS-BMST, we contact this donor and initiate all the steps for a successful blood stem cell donation. So far, we have arranged 29 successful donations and were thus able to offer 29 patients a second chance at life.
Other than blood cancers, what are the other focal areas of DKMS BMST Foundation India?
DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and aplastic anemia.
Our aim is to improve the situation of patients suffering from blood cancer and other blood disorders in India, by raising awareness about blood stem cell transplantation and registering potential blood stem cell donors. By doing this, DKMS-BMST provides patients in need of a blood stem cell transplant with a second chance at life.
How the ongoing COVID-19 pandemic has affected the treatment and diagnosis of hemoglobinopathy and other blood disorders?
Blood cancer and other blood disorder patients suffer from immune deficiency. Even regular respiratory viruses are a problem and the spread of coronavirus is a major risk for the patients. These patients are more sensitive to infection than any other group, because the treatment itself destroys their own immune system, and replaces it with the donors. Thus, the management of such high-risk patients have also become challenging in this situation. The Covid-19 pandemic had posed lot of challenges for patients with hematological-oncological conditions and in need of a blood stem cell transplant. In the context of unrelated blood stem cell transplants there is lots of logistic support needed. The lockdown situations used to impact the usual process for transporting blood stem cells across borders and countries. There was also a fear factor in the voluntary blood stem cell donors about blood stem cell donation during this time.
However, now the situation is getting better and we are registering potential donors through online and offline activities as well.
What are the common misconceptions that you come across related to blood cancers and other blood-related disorders in India?
A lack of understanding and multiple baseless misconceptions existing amongst people about the process, impacts the cause. People often mistake a blood stem cell transplant as a painful procedure. The blood stem cell donors need not undergo any surgical procedure as the stem cells are collected from the donors blood. The process followed is similar to donating blood platelets. It is high time that we all overcome these misconceptions and commit to being a lifesaver.
What are the challenges DKMS BMST Foundation India faces while recruiting Indian donors? What is the importance of recruiting young donors?
As the number of patients increase every year, the number of transplants increase proportionately. But the problem is, due to the lack of awareness and general misconception about stem cell transplants in India, there are only 0.04% of the population that are registered as potential blood stem cell donors. This makes it very difficult for a patient to be able to find an HLA (Human Leucocyte Antigen) matched donor. While misinformation and/or lack of information is the biggest challenge faced by all potential blood stem cell donors today, multiple myths associated with a stem cell donation pose a greater threat.
Some of the common myths include:
Myth: Donating blood stem cells means losing them forever.
Fact: When you donate your stem cells, you are only donating a fraction of your total stem cells.
All the cells will naturally be replenished within a few weeks
Myth: Donating stem cells is an invasive and painful process
Fact: Blood stem cells are collected through peripheral blood stem cell collection (PBSC) which is completely safe and a non-surgical procedure. The process is similar to blood platelet donation that takes approximately three to four hours to complete and the donor can leave the collection center the same day.
Myth: Blood Donation and a blood stem cell donation are same
Fact: Unlike blood collection for transfusion, blood stem cells are collected only when there is a match between the donor and patients Human leukocyte antigen (HLA) (tissue type).
So, you could be potentially be the only match and lifesaver for a person with blood cancer in need of a transplant. Blood stem cell donors donate only blood stem cells and the process is similar to a platelet donation.
Myth: Joining a blood stem cell registry is of no use. Most patients can find a stem cell donor within their own families.
Fact: Per statistics, only 30% of blood disorder patients in need of a stem cell transplant are able to find a sibling match. About 70 percent of patients need an unrelated donor.
What is the significance of Stem Cell Transplant as a treatment option?
Due to the advanced medical technologies and increased research, life-threatening diseases such as blood cancer can be treated through stem cell transplants. Stem cell transplantation is a procedure that restores blood-forming stem cells in people who have had theirs destroyed by the very high doses of chemotherapy or radiation therapy. Healthy blood stem cells from a matching donor is infused into the patient to help resume healthy blood production.
What are future plans for DKMS-BMST in India? In the coming years, what will be the status of India with respect to stem-cell therapies?
DKMS-BMST will continue working with its mission to help blood cancer and blood disorder patients by raising awareness, organizing donor registration events to recruit more potential blood stem cell donors of Indian origin, thus increasing the chances of finding matching donors for patient in need of a lifesaving stem cell transplant and facilitating successful blood stem cell donations. Since, ethnicity plays a crucial role in finding a matching donor, the ratio of potential blood stem cell donors from India needs to rise significantly.
Continue reading here:
Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder: Patrick Paul, CEO, DKMS BMST Foundation India - The Financial...
- Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech - March 28th, 2024
- Putting Stem Cell-Based Therapies in Context - National Institutes of ... - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 31st, 2024
- Stem Cell Transplant and CAR T-cell Therapy: The Patient and Care Partner Experience | BMT Infonet - BMT Infonet | - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- The Trouble With Stem Cell Therapy - Consumer Reports - December 20th, 2023
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- The stem cell therapy project Blue4Therapy brought to a highly successful close - Marketscreener.com - April 7th, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - December 27th, 2022
- How much does stem cell therapy cost in 2022? - The Niche - December 18th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - December 18th, 2022
- Ethical issues in stem cell research and therapy - December 10th, 2022
- EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing... - November 6th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 21st, 2022
- Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological... - October 21st, 2022
- Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO - October 13th, 2022
- Stem cell therapy and autism | Raising Children Network - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian - October 13th, 2022
- Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance - October 13th, 2022
- 2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau - October 13th, 2022
- Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and ... - October 4th, 2022
- Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the... - October 4th, 2022
- Innovative Imaging Techniques to Accelerate the Discovery of New... - Healthcare Tech Outlook - October 4th, 2022
- Celtic-mad dad left unable to talk after horror attack as family fundraise for stem cell therapy... - The Scottish Sun - September 25th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 16th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist - September 16th, 2022
- Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with... - September 16th, 2022
- T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma - Targeted Oncology - September 16th, 2022
- Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization - BioPharma-Reporter.com - September 16th, 2022
- BioRestorative Therapies : BRTX Presentation September 2022 - Marketscreener.com - September 16th, 2022
- Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights - September 16th, 2022
- IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 - BioSpace - September 16th, 2022
- The five hottest private biotech companies in India - Labiotech.eu - September 16th, 2022
- Be The Match and William G. Pomeroy Foundation Announce $500k Gift and Matching Campaign - PR Newswire - September 16th, 2022
- California man appears to be another person cured of HIV after a stem cell transplant - aidsmap - August 5th, 2022
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR... - August 5th, 2022
- Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga - August 5th, 2022
- The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal - August 5th, 2022
- World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire - August 5th, 2022
- Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire - August 5th, 2022
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With 'Favorable Survival Outcomes' in Group of Rare Blood Cancers - Curetoday.com - July 27th, 2022
- Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii - July 27th, 2022
- Petition calling for 'life-changing' MS treatment funding handed to Parliament - Stuff - July 27th, 2022
- How effective is stem cell therapy for liver cirrhosis? - Times of India - July 27th, 2022
- Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences - July 27th, 2022
- S'porean doctor, a sought-after top expert in cell therapy, appointed to WHO expert panel - The Straits Times - July 27th, 2022
- Top 10 Advances in Large B-Cell Lymphomas in the Past 10 Years - Targeted Oncology - July 27th, 2022
- Stem Cell Therapy Market Emerging Trends to Make Driving Growth on Key Players Status - Taiwan News - July 19th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 11th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 11th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 11th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 11th, 2022
- New sickle cell disease gene therapies depend on getting the right mouse - EurekAlert - July 11th, 2022
- Market Share, Supply, Analysis and Forecast of Human Insulin Drugs and Delivery Devices to 2026 Designer Women - Designer Women - July 3rd, 2022
- Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times - June 22nd, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 22nd, 2022
- Stem Cell Therapy in Jacksonville at Pangenics Regenerative Center - June 13th, 2022
- Stem-Cell Based Therapy Shows Promise in Treating High-Risk Type 1 Diabetes - Newswise - June 13th, 2022
- What Is Myelofibrosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention - Everyday Health - June 13th, 2022
- European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology - June 13th, 2022
- Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater... - June 4th, 2022
- Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News - June 4th, 2022
- Dedication, Achievement and Grace in Cancer Care - Curetoday.com - June 4th, 2022
- Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - June 4th, 2022
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News - June 4th, 2022
- CPX-351 in Treatment of AML and Clinical Considerations - OncLive - June 4th, 2022
- High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network - June 4th, 2022
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - May 15th, 2022
- Cell Culture Market to Gain US$ 27.6 Bn by 2031, Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth - BioSpace - May 15th, 2022
- Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL - OncLive - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7 - Benzinga - May 15th, 2022
- Vale man with MS needs 50,000 for treatment in Mexico - Evesham Journal - May 2nd, 2022
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO... - May 2nd, 2022
- Long-Term Axi-Cel Data 'May Be Suggestive of a Cure' in Patients With Large B-Cell Lymphoma - Curetoday.com - May 2nd, 2022
- Billy Connolly donates painting to Glasgow woman diagnosed with cancer five times - Glasgow Times - May 2nd, 2022
- The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN - Neurology Live - April 19th, 2022
- AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL - HealthDay News - April 19th, 2022
- 2022-04-18 | NDAQ:BRTX | Press Release | BioRestorative Therapies Inc - Stockhouse - April 19th, 2022
- First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial - Curetoday.com - April 6th, 2022